002019 Stock Overview
Engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Yifan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥11.85 |
| 52 Week High | CN¥16.73 |
| 52 Week Low | CN¥9.11 |
| Beta | 0.97 |
| 11 Month Change | -5.65% |
| 3 Month Change | 10.54% |
| 1 Year Change | -28.57% |
| 33 Year Change | -30.50% |
| 5 Year Change | -17.13% |
| Change since IPO | -25.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 002019 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.9% | 3.7% | 2.3% |
| 1Y | -28.6% | -5.7% | 5.6% |
Return vs Industry: 002019 underperformed the CN Pharmaceuticals industry which returned -5.7% over the past year.
Return vs Market: 002019 underperformed the CN Market which returned 5.6% over the past year.
Price Volatility
| 002019 volatility | |
|---|---|
| 002019 Average Weekly Movement | 6.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002019 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002019's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4,230 | Xian Feng Cheng | www.yifanyy.com |
Yifan Pharmaceutical Co., Ltd. engages in the researches and develops, produces, and sells macromolecules, biosimilars, generic drugs, small molecules, synthetic biologics, and special traditional Chinese medicines in China Southeast Asia, Europe, North America, Singapore, South Korea, Italy, Germany, and the United States, and internationally. It offers oral slow controlled release preparations, micron suspensions, micelles for injection, and liquid preparations. The company also focuses on hematologic maliganancies, inflammatory, endocrinology/metabolic, dermatological, gynecologic, and pediatric diseases, etc. The company was formerly known as Yifan Xinfu Pharmaceutical Co., Ltd.
Yifan Pharmaceutical Co., Ltd. Fundamentals Summary
| 002019 fundamental statistics | |
|---|---|
| Market cap | CN¥14.41b |
| Earnings (TTM) | -CN¥331.54m |
| Revenue (TTM) | CN¥5.00b |
2.9x
P/S Ratio-43.5x
P/E RatioIs 002019 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002019 income statement (TTM) | |
|---|---|
| Revenue | CN¥5.00b |
| Cost of Revenue | CN¥2.71b |
| Gross Profit | CN¥2.28b |
| Other Expenses | CN¥2.62b |
| Earnings | -CN¥331.54m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 45.73% |
| Net Profit Margin | -6.64% |
| Debt/Equity Ratio | 29.2% |
How did 002019 perform over the long term?
See historical performance and comparison